Qualigen Therapeutics, Inc.

For the period ended Mar 31, 2025. Filed Jul 21, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed Jul 21, 2025

FFR$0.89-1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

Convertible · Total
Preferred Stock · Common Stock · Additional · Stockholders’
	Shares	Amount	Shares	Amount	Paid-In Capital	Accumulated Deficit	Equity (Deficit)
Balance at December 31, 2024	6,256	$5,716,400	736,431	$65,314	$119,958,897	$(123,061,575)	$2,679,036
Issuance of common stock for the conversion of Series A-2 preferred shares	(3,236)	(2,893,306)	888,879	889	2,892,417	—	—
Stock-based compensation	—	—	—	—	269	—	269
Net loss	—	—	—	—	—	(2,646,172)	(2,646,172)
Balance at March 31, 2025	3,021	$2,823,094	1,625,310	$66,203	$122,851,583	(125,707,745)	$33,134

Convertible · Total
Preferred Stock · Common Stock · Additional · Stockholders’
	Shares	Amount	Shares	Amount	Paid-In Capital	Accumulated Deficit	Equity (Deficit)
Balance at December 31, 2023	—	$—	107,243	$43,262	$114,655,565	$(116,802,384)	$(2,103,557)
Monthly redemptions of convertible debt into common stock	—	—	22,771	1,138	545,094	—	546,232
Fair value of warrant modification for professional services	—	—	—	—	9,737	—	9,737
Stock-based compensation	—	—	—	—	58,651	—	58,651
Net loss	—	—	—	—	—	(2,032,751)	(2,032,751)
Balance at March 31, 2024 (after stock split)	—	$—	130,014	$44,400	$115,269,047	$(118,835,135)	$(3,521,688)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.